Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood–Derived NK Cells Facilitates CAR-like Responses Against CD30+ Malignancies - Concepedia

Concepedia

Publication | Open Access

Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood–Derived NK Cells Facilitates CAR-like Responses Against CD30+ Malignancies

DOI Full Paper Access

147

Citations

33

References

2021

Year

Lucila Nassif Kerbauy, Nancy D. Marín, Mecit Kaplan, Pinaki P. Banerjee, Melissa M. Berrien-Elliott, Michelle Becker‐Hapak, Rafet Başar, Mark P. Foster, Luciana Garcia Melo, Carly C. Neal,

Clinical Cancer Research

Abstract

We identify AFM13 as a promising combination with cytokine-activated adult blood or cord-blood NK cells to treat CD30<sup>+</sup> hematologic malignancies, warranting clinical trials with these novel combinations.

References

	Year	Citations

Page 1